BenzingaAugust 7, 2026 at 3:37 PM NY28 days ago

UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story